Iron Carbonyl Shortage: What Providers and Prescribers Need to Know in 2026

Iron Carbonyl (carbonyl iron) remains off the FDA and ASHP drug shortage lists as of 2026. However, providers across the country are fielding calls from patients who can't locate Feosol Natural Release, Icar, or generic carbonyl iron tablets at their local pharmacies. This guide provides clinical context and practical guidance for managing patients on Iron Carbonyl therapy when supply is intermittent.

Current Supply Status: No National Shortage

Pharmaceutical-grade carbonyl iron powder is manufactured globally by multiple producers including BASF (Germany), Jinchuan Group (China), American Carbonyl (Alabama), and suppliers in India. The U.S. market entered 2026 with well-balanced inventory levels and slight price softening — indicative of adequate supply rather than scarcity.

Localized stock-outs are driven by retail distribution dynamics, not upstream manufacturing failures. The issue is primarily one of shelf allocation priority (ferrous sulfate dominates retail iron supplement SKUs) and distributor-level stocking decisions for a lower-volume OTC product.

Clinical Profile Recap: Why Carbonyl Iron Is Prescribed

Providers typically choose carbonyl iron over ferrous sulfate for one or more of the following reasons:

• Pediatric safety: Carbonyl iron's slow gastric conversion mechanism significantly reduces the risk of fatal iron overdose in young children. Clinical studies have demonstrated that oral doses of 10,000 mg were tolerated by volunteers without toxicity, in stark contrast to ferrous sulfate's narrow pediatric therapeutic window.
• GI tolerability: For patients who discontinue ferrous sulfate due to nausea, constipation, or epigastric pain, carbonyl iron may offer improved adherence despite similar GI side effects at equivalent iron doses.
• Patient preference: Some patients are specifically aware of and prefer carbonyl iron, particularly pregnant patients who read about pediatric safety.

It is important to note that on a milligram-for-milligram basis, carbonyl iron has approximately 70% the bioavailability of ferrous sulfate, and clinical trials have not demonstrated a significant efficacy advantage over standard ferrous sulfate doses. The primary advantage is the safety profile, not superior iron repletion.

Dosing Reference for Iron Carbonyl

For provider reference, standard Iron Carbonyl dosing is:

• Adults (iron deficiency anemia): 45–90 mg elemental iron per day (one to two 45 mg Feosol Natural Release tablets), with or without vitamin C for absorption enhancement.
• Pediatric prophylaxis: 1–2 mg elemental iron/kg/day (max 15 mg/day) in 1–2 divided doses.
• Pediatric IDA: 3–6 mg elemental iron/kg/day divided every 8–12 hours (maximum 6 mg/kg/day).
• Duration: Continue for 6–8 weeks after hemoglobin normalization to replenish iron stores; reassess at 3 months.

Clinical Alternatives When Iron Carbonyl Is Unavailable

When a patient cannot access carbonyl iron, consider these evidence-based alternatives:

• Ferrous gluconate (OTC): 28–36 mg elemental iron per 325 mg tablet; lower GI burden per dose than ferrous sulfate; reasonable substitute in adults without children at home.
• Ferrous fumarate (OTC): 33% elemental iron; common in prenatal formulations; available OTC.
• Ferric maltol (Accrufer, Rx): FDA-approved 2019; 30 mg elemental iron twice daily; stable absorption at variable gastric pH; suitable for IBD or CKD patients; prior auth may apply.
• Iron polysaccharide complex (OTC/Rx): Niferex, NovaFerrum — anecdotally better tolerated, though evidence is limited vs. ferrous salts.
• IV iron (Injectafer, Monoferric, Venofer, Feraheme): Reserve for patients with malabsorption, severe IDA, ongoing significant blood loss, or documented intolerance to multiple oral formulations.

Key Drug Interactions to Counsel Patients On

These interactions apply to all oral iron formulations, including carbonyl iron:

• Tetracyclines and fluoroquinolones: separate by at least 2–6 hours to prevent chelation and reduced antibiotic absorption.
• Levothyroxine: separate by at least 4 hours; iron significantly reduces T4 absorption.
• Levodopa: iron reduces levodopa absorption; separate administration by at least 2 hours.
• Proton pump inhibitors and antacids: significantly reduce iron absorption by increasing gastric pH; counsel patients to take iron before or between PPI doses.
• Baloxavir marboxil (Xofluza): avoid concurrent use; iron significantly reduces baloxavir plasma levels.

How medfinder Helps Your Patients Stay on Therapy

When patients call your office reporting they can't find their iron supplement, consider directing them to medfinder for providers. medfinder calls pharmacies near the patient to confirm which ones have Iron Carbonyl in stock, then texts the patient with results. This keeps patients on their prescribed therapy rather than self-substituting with a different formulation.

Monitoring Parameters for Iron Deficiency Anemia Treatment

Regardless of which iron formulation a patient uses, the following monitoring is recommended:

• Reticulocyte count at 1–2 weeks: Should rise, confirming adequate absorption and erythropoietic response.
• Hemoglobin at 4–8 weeks: Should begin rising; normalization typically occurs at 3–6 months.
• Serum ferritin at 3–6 months: Target > 30 ng/mL after Hgb normalization; continue supplementation 6–8 weeks beyond Hgb normalization to replenish stores.
• Address the underlying cause: Iron supplementation alone without identifying and treating the source of blood loss is insufficient for long-term management.